상세정보

Intro -- Preface -- Contents -- Contributors -- Part I: Stroke Neuroprotection: The History and Learning Experience -- Chapter 1: Reflections on Neuroprotection Research and the Path Toward Clinical Success -- 1 Introduction: A Brief Chronological History of Stroke -- 1.1 Of Neurons and Time -- 1.1.1 Extrapolated Stroke and Cerebrovascular Disease Incidence -- 1.1.2 Time–brain matters! -- 2 Limited Benefit Treatment Options for Acute Ischemic Stroke Victims: Successes! -- 2.1 Thrombolysis: Thrombolytic Therapy -- 2.2 Endovascular Procedures and Thrombolysis -- 2.2.1 ESCAPE [32]: Table 1.3 -- 2.2.2 EXTEND-IA [33]: Table 1.4 -- 2.2.3 MR CLEAN [31]: Table 1.5 -- 2.2.4 REVASCAT [34]: Table 1.6 -- 2.2.5 SWIFT-PRIME [35]: Table 1.7 -- 2.2.6 Endovascular Procedure Benefit -- 2.3 Embolectomy Concerns -- 2.3.1 Patient Population Selection for Embolectomy and Thrombolysis -- 2.3.2 Limitations of the Trials -- Patient Selection Bias -- Saving Penumbra -- Time to Treatment -- Coadministration of Thrombolytics -- 2.3.3 Future of Embolectomy -- Endovascular Procedure Summary -- 3 Neuroprotection -- 3.1 Evolving Opportunities -- 3.2 The RIGORs of Drug Development: Guideline Adherence -- 3.3 Meta-analysis of Translational Studies -- 4 Comorbidities and Models -- 4.1 Hypertension Models -- 4.2 Diabetic Models -- 4.2.1 Coadministration of Drugs in Stroke Models -- 5 Drug Development Considerations -- 6 Conclusion -- References -- Chapter 2: Systematic Review and Meta-analysis: Important Tools in Understanding Drug Development for Stroke -- 1 Introduction -- 2 Evidence-Based Approaches to Understanding Translational Stroke Research -- 2.1 Assessing the Quality and Range of Available Evidence -- 2.1.1 Quality of Evidence -- 2.1.2 Range of Evidence -- 2.2 Assessing for Publication Bias -- 2.3 Impacts of Systematic Reviews -- 2.4 Providing Potential Explanations for Discrepancies Between Preclinical and Clinical Trial Results -- 2.5 Informing Clinical Trial Design -- 3 Limitations of Systematic Review and Meta-analysis -- 4 Future of Preclinical Systematic Review and Meta-analysis -- 5 Conclusions -- 6 Resources -- References -- Chapter 3: Neuroprotection Is Technology, Not Science -- 1 Introduction -- 2 Part 1: Physics and Biology -- 2.1 A Tale of Two Cultures -- 2.2 What Is Measured? -- 2.3 The Mathematizing of Biology -- 3 Part 2: A Theory of Acute Cell Injury -- 3.1 Introduction to the Theory -- 3.2 Qualitative Description of the Theory -- 3.3 The Autonomous Theory -- 3.4 Solutions of the Autonomous Theory -- 3.5 Monostable Outcome -- 3.6 Bistable Outcome -- 3.7 Pre-treatment Therapies -- 3.8 Closed Trajectories and the Autonomous Theory -- 4 Technological Applications -- 4.1 Approaches to Therapy -- 4.2 Ascertaining Injury Intensity -- 4.3 Protective Therapeutics -- 4.4 The Non-autonomous Dynamical Theory of Acute Cell Injury -- 4.5 Sequential Injuries -- 4.6 Solutions of the Multiple Injury Model -- 4.6.1 Preconditioning -- 4.6.2 Post-injury Drug Treatment -- 4..